LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

431.57 0.22

Buy Sell

Overview

Share price change

24h

Current

Min

417.04

Max

432.91

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+60.55% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-661M 9.9B
Previous open	431.35
Previous close	431.57

News Sentiment

By Acuity

45%

55%

136 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 mar 2026, 18:13 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9 mar 2026, 17:20 UTC

Major News Events

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9 mar 2026, 17:15 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10 mar 2026, 00:00 UTC

Major News Events

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9 mar 2026, 23:52 UTC

Market Talk

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9 mar 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 23:46 UTC

Market Talk

Major News Events

Correction to Crude Prices Market Talk on March 9

9 mar 2026, 23:42 UTC

Market Talk

Major News Events

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9 mar 2026, 23:08 UTC

Major News Events

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9 mar 2026, 23:07 UTC

Major News Events

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9 mar 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9 mar 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 mar 2026, 20:47 UTC

Major News Events

The 24 Hours When Oil Markets Went Wild -- WSJ

9 mar 2026, 20:33 UTC

Major News Events

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9 mar 2026, 20:14 UTC

Market Talk

Major News Events

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9 mar 2026, 19:33 UTC

Major News Events

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9 mar 2026, 19:17 UTC

Market Talk

Major News Events

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9 mar 2026, 19:14 UTC

Market Talk

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9 mar 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

9 mar 2026, 18:23 UTC

Market Talk

Major News Events

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9 mar 2026, 17:58 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9 mar 2026, 17:57 UTC

Acquisitions, Mergers, Takeovers

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9 mar 2026, 17:41 UTC

Major News Events

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9 mar 2026, 17:41 UTC

Market Talk

Major News Events

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9 mar 2026, 17:08 UTC

Market Talk

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9 mar 2026, 17:04 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 17:04 UTC

Market Talk

Major News Events

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

60.55% upside

12 Months Forecast

Average 694.9 USD 60.55%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

136 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.